HC Wainwright & Co. Maintains Buy on Zymeworks, Raises Price Target to $55

Benzinga · 4d ago
HC Wainwright & Co. analyst Robert Burns maintains Zymeworks (NASDAQ:ZYME) with a Buy and raises the price target from $51 to $55.